(Q34585315)

3 August 2017

1 reference

title

Review article: monitoring for drug side-effects in inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

3 August 2017

0 references

inflammation

0 references

author name string

Cunliffe RN

series ordinal

1

1 reference

PubMed ID

11929382

3 August 2017

Scott BB

series ordinal

2

1 reference

PubMed ID

11929382

3 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

Alimentary Pharmacology & Therapeutics

3 August 2017

1 reference

3 August 2017

16

1 reference

3 August 2017

4

1 reference

3 August 2017

647-662

1 reference

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

3 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Comparative tolerability of treatments for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Sulfasalazine. Adverse effects and desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Role of sulphasalazine in the aetiology of folate deficiency in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

A controlled double blind study of azathioprine in the management of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

The clinical pharmacology of 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Rational dosing of azathioprine and 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Low-dose oral methotrexate in refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Methotrexate in refractory Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Efficacy of parenteral methotrexate in refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Comparative trial of sulphasalazine and oral sodium cromoglycate in the maintenance of remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Hypersensitivity to salicylazosulfapyridine: renal and hepatic toxic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Mesalazine-associated interstitial nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Chronic interstitial nephritis due to 5-aminosalicylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Nephrotoxicity due to azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Sulfasalazine-induced fulminant hepatic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Mesalamine-induced granulomatous hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Cholestasis associated with mesalazine therapy in a patient with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Mesalazine (5-aminosalicylic acid) induced chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Cyclosporin for inflammatory bowel disease: mechanisms and possible actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Immunosuppressant-induced nephropathy: pathophysiology, incidence and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01216.X

10.1046/J.1365-2036.2002.01216.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

11929382